Forte Biosciences (NASDAQ:FBRX) Bolsa, Quote.MetaTitle.unusual-options

Forte Biosciences

Forte Biosciences Inc

Agenus

Anika Therapeutics

Anixa Biosciences

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

Compugen

Coherus Oncology

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Caribou Biosciences

Elicio Therapeutics

Genfit

Genelux

Heron Therapeutics

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Seres Therapeutics

Molecular Partners AG - American Depositary Shares

Molecular Partners

Nuvectis Pharma

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Exagen

Forte Biosciences (FBRX) Previsión

Noticias

Beneficios

Opciones

Calificaciones de analistas

Operaciones de insiders

Interés en corto

Informe de acciones

Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).

Comments

Forte Biosciences Opciones Inusuales

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL